中国肝脏病杂志(电子版)

位置：首页 >> 期刊文章

恩替卡韦联合护肝布祖热颗粒治疗维吾尔族、汉族慢性乙型肝炎患者的疗效比较

作者：张剑1 买买提江 · 吾布力 2 李俊红 1

单位：1. 首都医科大学附属北京佑安医院急诊科北京 100069 2. 新疆和田地区传染病医院肝病科新疆和田 848000

关键词：恩替卡韦护肝布祖热颗粒维吾尔族汉族肝炎乙型慢性

分类号：

出版年,卷(期):页码：2016,8(1):44-48

摘要：

摘要：目的比较恩替卡韦联合护肝布祖热颗粒治疗维吾尔族、汉族慢性乙型肝炎患者的临床疗效。
方法采取前瞻性、配对研究方法，选取2015年1月至2015年5月新疆和田地区传染病医院就诊的初始
治疗的慢性乙型肝炎患者为试验组，维吾尔族∶汉族按照4∶1配对分组，维吾尔族300例，汉族75
例，均接受恩替卡韦联合护肝布祖热颗粒治疗12周，随机抽取20例汉族慢性乙型肝炎患者与80例维吾
尔族慢性乙型肝炎患者为对照组，仅使用恩替卡韦治疗12周。观察各组患者病毒学应答率、血清学应
答率、生物化学应答率以及不良反应发生率。结果治疗4周、8周、12周病毒完全应答率分别为：试
验组中维吾尔族9.0%、20.7%、30.3%，汉族8.0%、21.3%、29.3%，对照组中维吾尔族2.5%、12.5%、
21.3%，汉族5.0%、10.0%、20.0%；部分应答率分别为：试验组中维吾尔族48.3%、64.3%、69.3%，
汉族46.7%、62.7%、64.0%，对照组中维吾尔族46.3%、62.5%、66.3%，汉族45.0%、65.0%、
65.0%；生化学应答率分别为：试验组中维吾尔族88.7%、94.7%、99.3%，汉族85.3%、90.6%、
98.6%，对照组中维吾尔族83.8%、87.5%、96.3%，汉族85.0%、90.0%、95.0%；血清学应答率分别
为：试验组中维吾尔族31.7%、汉族29.3%、对照组中维吾尔族和汉族均为45.0%。治疗前后各组患者
均未见明显脏器功能损伤。结论恩替卡韦联合护肝布祖热颗粒治疗维吾尔族慢性乙型肝炎患者的疗
效比治疗汉族慢性乙型肝炎患者的疗效更好。

Abstract: Objective To compare the efficacy of combination of Huganbuzure granule and entecavir in
treatment of Uygur and Han patients with chronic hepatitis B. Methods A forward, paired research method was
applied and chronic hepatitis B patients with initial treatment in Hotan Infectious Diseases Hospital from January
2015 to May 2015 were selected as the experimental group. Total of 300 cases were Uygur CHB patients and 75
cases were Han CHB patients, they were treated with entecavir and Huganbuzure particles for 12 weeks. Twenty
cases of Uygur CHB patients and 80 cases of Han CHB patients were randomly selected as the control group and
were treated with entecavir only, the Uygur∶Han was 4∶1 for pairing. The virologic response rate, serological
response rate, biochemical response rate and incidence of adverse reactions were observed. Results After
treating for 4 weeks, 8 weeks and 12 weeks, the virus complete response rate in the experimental group were
9.0%, 20.7% and 30.3% in Uighur and 8.0%, 21.3% and 29.3% in Han patients, the virus complete response
rate in the control group were 2.5%, 12.5% and 21.3% in Uighur and 5.0%, 10.0% and 20.0% in Han patients,

respectively; the partial response rate in the experimental group were 48.3%, 64.3% and 69.3% in Uighur and
46.7%, 62.7% and 64.0% in Han patients, the partial response rate in the control group were 46.3%, 62.5% and
66.3% in Uighur and 45.0%, 65.0% and 65.0% in Han patients, respectively; the biochemical response rate in the
experimental group were 88.7%, 94.7% and 99.3% in Uighur and 85.3%, 90.6% and 98.6% in Han patients, the
biochemical response rate in the control group were 83.8%, 87.5% and 96.3% in Uighur and 85.0%, 90.0% and
95.0% in Han patients, respectively; the serological response in Uighur and Han patients were 31.7% and 29.3%
in the experimental group, and 45.0% in the control group. All groups showed no significant organ dysfunction
before and after treatment. Conclusion The efficacy of entecavir combined with Huganbuzure granule in
treatment of Uygur patients with chronic hepatitis B was better than that of Han patients.

基金项目：

作者简介：

参考文献：

服务与反馈：

【文章下载】【加入收藏】